MedTrace Logo

The Boceprevir and Sildenafil Pharmacokinetics Study

NCT01499498 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-06-21

Study results available
· View outcomes & findings →

Summary

This is a healthy volunteer study looking at the interactions between two drugs: boceprevir and sildenafil.

New drugs are being developed to treat people with the chronic viral infection hepatitis C. Very little is know how these new treatments interact with other medications such as the drugs used to treat erectile dysfunction.

The purpose of this study is to look at levels of both a new hepatitis C drug called boceprevir (BOC) and an existing erectile dysfunction drug called sildenafil to see if they affect the blood levels of each other when given separately and together.

Conditions

  • Hepatitis C

Interventions

DRUG

Sildenafil and Boceprevir

25mg once/800mg three times a day

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Alan Winston, MBChB MD · Imperial College London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-04-30
Completion
2014-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499498 on ClinicalTrials.gov